Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 191

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 16A
Chunk 191
---
 voting rights, or private placements as a result            
  of which a person will become a controlling shareholder of the company, subject to certain exemptions and exceptions. In addition, under          
  the Israeli Companies Law, a merger generally requires approval of the shareholders of each of the merging companies; and                         
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Otherwise, we comply with the rules generally applicable
to U. S. domestic companies listed on The Nasdaq Global Market. However, we may in the future decide to use the foreign private issuer
exemption with respect to some or all of the other Nasdaq corporate governance rules.

ITEM 16H. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 16I. DISCLOSURE REGARDING FOREIGN
JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

ITEM 16J. INSIDER TRADING POLICIES

We have adopted an Insider Trading Compliance Policy,
which, among other things, governs the purchase, sale and other dispositions of our securities by our directors, executive officers and
employees. Our Insider Trading Compliance Policy aims to promote compliance with applicable insider trading laws, rules and regulations,
and Nasdaq listing standards. A copy of our Insider Trading Compliance Policy is filed as Exhibit 11.1 to this Annual Report.

ITEM 16K. CYBERSECURITY

We operate in the medical device sector, which is
subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including
intellectual property theft; fraud; extortion; harm to employees or customers; violation of privacy laws and other litigation and legal
risk; and reputational risk. We recognize the critical importance of developing, implementing, and maintaining cybersecurity measures
to safeguard our information systems and protect the confidentiality, integrity, and availability of our data. We currently have security
measures in place to protect information we may have on our employees, vendors, and in some cases (for example, in our clinical trial
data sets) patients, as well as to prevent data loss and other security breaches.

Our current cybersecurity risk assessment and protection
program consists of various cybersecurity software features and capabilities designed to protect our systems and alert us of any cybersecurity
incidents, such as software to strengthen protection against targeted attacks and previously unknown exploits, a network intrusion detection
system, firewall and router features enabling unified threat management, load balancing, multi Wide Area Network (WAN